Medicaid expansion has brought an additional 11 million people under this public insurance umbrella. Dr Arthur Vercillo, regional president of Excellus Blue Cross Blue Shield, says that state governments may continue to depend on the private sector to manage Medicaid costs and “get these patients into a system of physicians and hospitals who previously didn’t want to take care of Medicaid patients.”
Some states have opted out of the Medicaid expansion, which is a concern for Francois de Brantes, executive director of the Healthcare Incentives Improvement Institute. “The expansion of Medicaid in many states has been able to capture the layer above the poorest of the poor who have been priced out of the commercial insurance market,” he comments. From a policy perspective, it is difficult to justify leaving individuals out of the health insurance system. States have to realize that “It just doesn’t make a whole heck of a lot of sense [to ignore Medicaid expansion] from a pure economic standpoint, and certainly from a social standpoint,” says Mr de Brantes, adding, “I’ve run out of any ability to explain it.” Dr Vercillo agrees, but says it is a case of politics rather than economics overriding good patient care.
“The ACA was a deal, and like any deal, compromises have to be made,” Mr de Brantes. However, the fundamental premise was to try to provide health insurance for a significant proportion of the population who lacked it for various reasons, such as affordability.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More